Pfizer is a research-based biopharmaceutical company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products, and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical segment includes the primary and specialty care, established products, emerging markets and oncology customer-focused units. Diversified segment offers animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. 

Show more
TypePublic
HQNew York, US
Founded1849
Size (employees)90,200 (est)-6%
Websitepfizer.comwdxefcqufszuzezftuxetqsqxt
Pfizer was founded in 1849 and is headquartered in New York, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Pfizer

Ian C. Read

Ian C. Read

Chairman of the Board and Chief Executive Officer
Albert Bourla

Albert Bourla

Chief Operating Officer, Pfizer
Frank D'Amelio

Frank D'Amelio

Executive Vice President, Business Operations and Chief Financial Officer
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research and Development of Pfizer Inc
Michael Goettler

Michael Goettler

Executive Vice President, Pfizer
Angela Hwang

Angela Hwang

Group President, Pfizer Essential Health
Show more

Pfizer Office Locations

Pfizer has offices in Surrey, Zürich, Sollentuna, Alcobendas and in 36 other locations
New York, US (HQ)
235 E 42nd St
Buenos Aires, AR
Panamericana Collector 1804, 1st Floor - Sector B - South Side
Melrose Park, AU
38-42 Wharf Rd
Wien, AT
1 Floridsdorfer Hauptstraße
Minsk, BY
403 8 praspiekt Dziaržynskaha
Ixelles, BE
17 Boulevard de la Plaine
Show all (40)
Report incorrect company information

Pfizer Financials and Metrics

Pfizer Revenue

Embed Graph
Pfizer's revenue was reported to be $52.82 b in FY, 2016 which is a 8.1% increase from the previous period.
USD

Revenue (Q2, 2019)

26.4b

Gross profit (Q2, 2019)

20.9b

Gross profit margin (Q2, 2019), %

79.2%

Net income (Q2, 2019)

7.4b

Market capitalization (15-Oct-2018)

252.8b

Closing stock price (15-Oct-2018)

43.1

Cash (1-Jul-2018)

2.7b

EV

279.0b
Pfizer's current market capitalization is $252.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

51.6b49.6b48.9b52.8b

Revenue growth, %

(4%)(2%)8%

Cost of goods sold

9.6b9.6b9.6b12.3b

Gross profit

42.0b40.0b39.2b40.5b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017Q1, 2019Q2, 2019

Revenue

12.6b11.4b12.8b12.4b10.9b11.9b12.1b12.9b12.9b26.4b

Cost of goods sold

2.3b2.0b2.5b2.4b1.8b2.6b5.5b

Gross profit

10.4b9.3b10.3b10.0b9.0b10.3b20.9b

Gross profit Margin, %

82%82%81%81%83%80%79%
Annual
usdY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.2b10.1b2.2b3.3b3.6b

Inventories

6.2b5.7b

Current Assets

56.2b57.7b43.8b38.9b

PP&E

12.4b11.8b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017Q1, 2019Q2, 2019

Cash

2.1b2.9b3.4b2.4b3.6b3.7b3.1b2.3b2.7b

Inventories

6.5b6.1b6.2b6.4b5.8b5.8b7.6b7.6b8.1b8.1b

Current Assets

59.5b57.8b58.3b57.0b49.4b51.7b45.0b38.5b41.3b43.8b35.9b36.4b34.8b37.3b

PP&E

12.4b12.3b12.2b12.0b11.5b11.4b13.7b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1b9.2b

Inventories

(538.0m)175.0m(199.0m)365.0m

Accounts Payable

382.0m297.0m254.0m871.0m

Cash From Operating Activities

17.8b16.9b14.5b15.9b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2017Q1, 2019Q2, 2019

Net Income

2.6b2.3b2.9b2.7b2.4b3.6b7.4b

Depreciation and Amortization

3.1b1.6b3.1b

Cash From Operating Activities

4.8b2.0b5.8b

Purchases of PP&E

(806.0m)(386.0m)(810.0m)
USDY, 2018

EV/CFO

47.9 x

Financial Leverage

2.4 x
Show all financial metrics

Pfizer Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Active Clinical Studies

448 338

Phase III Trials Products

22 30 34 29

Discovery Projects

91 90 96 87

Vaccines Delivered

135 m
Show all operating metrics

Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
MedivationAugust 22, 2016$14 b
Anacor PharmaceuticalsJune 24, 2016$5.20 b
AllerganNovember 23, 2015$160 b

Pfizer Revenue Breakdown

Embed Graph

Pfizer revenue breakdown by business segment: 18.6% from GIP, 17.0% from VOC, 35.6% from Innovative Products and 28.7% from Established Products GEP

Report incorrect company information

Pfizer Online and Social Media Presence

Embed Graph
Report incorrect company information

Pfizer News and Updates

AMCP Foundation and Pfizer Offered Summer Internships in Managed Care Pharmacy

ALEXANDRIA, Va., Oct. 19, 2018 /PRNewswire/ -- The Academy of Managed Care Pharmacy (AMCP) Foundation is delighted to announce that six student pharmacists from across the country recently completed summer internship programs organized by the Foundation and supported by Pfizer, Inc. The...

UPDATE 1-Australian watchdog's appeal against Pfizer ruling dismissed by court

Australia's competition watchdog said on Friday the High Court dismissed its special leave application to appeal a court's decision on whether Pfizer Inc's local unit used its market power to limit competition for its cholesterol-lowering drug Lipitor.

Dow stocks Pfizer and UnitedHealth could be safety plays amid market volatility

In a wild week for the Dow, one corner of the index has proven immune to the worst of the volatility: health care. Dow stocks Pfizer, UnitedHealth and Merck remain within reach of 52-week highs.

Merck, Pfizer combo treatment meets main goals of kidney cancer trial

(Reuters) - Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer.

Pfizer Offers Early Retirement to U.S. Employees Ahead of Layoffs

The pharmaceutical company is expected to cut roughly 2% of its 90,000 employees worldwide in an effort to restructure.
Show more
Report incorrect company information

Pfizer Company Life and Culture

Report incorrect company information